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Abstract 
Background: Transcranial direct current stimulation (tDCS) is a novel non-pharmacological intervention being investigated for the treatment of major de-
pressive disorder (MDD). Objective: To perform an updated review of tDCS for MDD. Method: Systematic review in Medline/PubMed and other databases 
of all clinical studies evaluating the clinical efficacy of tDCS in MDD, from the first date available to December/2013. Results: Out of 55 articles, 24 were 
included, being 6 open-label studies; 8 randomized, double-blind, sham-controlled trials; 2 follow-up studies; 2 meta-analyses and 6 case reports. We observed 
an improvement of 20-40% in depressive symptoms, being slightly better in open studies. Five randomized clinical trials displayed positive results. The meta-
-analyses presented mixed results; although none included the study of Brunoni et al. (2013) that represents almost 50% of the evaluated sample. Open-label 
studies and case reports also investigated tDCS in bipolar depression, post-stroke depression and employed different parameters of stimulation. Discussion: 
TDCS is a novel, promising treatment for MDD. Definite evidence from large, ongoing clinical trials will be available in the next years. 
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Resumo
Contexto: A estimulação transcraniana por corrente contínua (ETCC) é uma nova intervenção não farmacológica investigada como tratamento no trans-
torno depressivo maior (TDM). Objetivo: Apresentar uma revisão atualizada da ETCC no TDM. Método: Revisão sistemática no banco de dados Medline/
PubMed e outros de todos os estudos clínicos publicados avaliando a eficácia da ETCC no TDM, da primeira data disponível a dezembro/2013. Resultados: 
De 55 artigos, 24 foram incluídos, sendo 6 estudos abertos; 8 ensaios clínicos randomizados, duplo-cego, placebo controlados; 2 estudos de seguimento; 2 
metanálises e 6 relatos de caso. Observa-se uma melhora de 20-40% nos sintomas depressivos, sendo ligeiramente maior nos estudos abertos. Entre os ensaios 
controlados, 5 demonstraram eficácia da técnica. As metanálises divergiram quanto aos resultados, mostrando presença e ausência de eficácia e ausência da 
ETCC. Porém, nenhuma incluiu o estudo de Brunoni et al. (2013), que representa quase 50% da população estudada. Estudos abertos e relatos de caso também 
investigaram o uso da ETCC na depressão bipolar, na depressão pós-AVC e usaram variações nos parâmetros de estimulação. Conclusões: A ETCC é uma 
técnica promissora no tratamento da TDM. Evidências definitivas devem estar disponíveis nos próximos anos, com a divulgação de resultados de grandes 
ensaios clínicos em andamento.
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Introduction
The use of electricity as a clinical treatment is not novel in medical 
literature. For instance, there are reports of using the “torpedo-fish” 
to treat pain since the Ancient times1. Nonetheless, the controlled 
use of electric currents for medical disorders only begun in the 18th 
century, with the development of the voltaic pile – even though, the 
application of electric currents over one’s scalp was still erratic and 
poorly executed2. In 1960s and 1970s there are reports of a method 
of non-invasive brain stimulation named “brain polarization”, quite 
similar to modern transcranial direct current stimulation (tDCS), 
which could enhance mood and alertness in healthy volunteers3 and 
treat depression4,5. Later on, this method was largely abandoned, 
possibly due to the advancement of psychopharmacology6 and the 
social stigma of electroconvulsive therapy (ECT) that hindered the 
development of other forms of non-invasive brain stimulation. 
In fact, tDCS was only reappraised as a neuromodulatory tool 
in the turn of the 21st century, with the seminal works of Priori et 
al.7 and Nitsche and Paulus8 who showed that the induction of a 
weak, direct current through electrodes placed over the scalp could 
increase (anode) and decrease (cathode) cortical excitability beyond 
the period of stimulation. Notwithstanding its exact mechanisms of 
action being still elusive, tDCS probably operates by inducing small 
changes (< 1mV) in the membrane potential9, thus acting in the 
frequency of spike timing and modifying net cortical excitability10. 
The mechanisms of action of tDCS occur also at the synaptic level. 
For instance, glutamate antagonists abolish tDCS after-effects, while 
NMDA-agonists enhance them11.
Moreover, tDCS presents a low rate of adverse effects and is a 
safe technique when used according to the standard procedures. In a 
recent systematic review of clinical studies, our group12 observed the 
lack of serious adverse effects associated with tDCS; with the excep-
http://dx.doi.org/10.1590/0101-60830004111520
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tion of one case of skin burn13. In an animal study of safety, Liebetanz 
et al.14 showed, in an animal study of safety, that cathodal-induced 
brain lesions only occurred when the stimulation intensities almost 
one hundred times higher than used in clinical studies. In addition, 
tDCS does not adversely affect brain and heart activity, respectively 
measured using EEG and EKG records15-17. In fact, the only adverse 
effect particularly associated with tDCS is skin redness18 – even 
though, this effect is mild and does not seem to compromise blind-
ing in sham-controlled tDCS trials19, which consist in turning off the 
device after < 30-60 seconds of stimulation, remaining turned off 
until the end of the session20. Finally, tDCS is, compared to repeti-
tive transcranial magnetic stimulation (rTMS), a relatively cheaper, 
easier to use, more portable technique with even less adverse effects. 
Such appealing characteristics motivated the research of using 
tDCS for the treatment of neuropsychiatric disorders (for a review 
see21), and, among them, tDCS has been showing particularly posi-
tive results in major depression, with the anode positioned over the 
left dorsolateral prefrontal cortex (DLPFC) and the cathode over 
the right DLPFC, the right supraorbital area or in an extra-cephalic 
position2. The rationale for using this montage in depression rests 
on: (1) the prefrontal asymmetry theory of depression, with relative 
hypoactivity over the left and relative hyperactivity over the right22,23; 
(2) the improvement in working memory and affective processing 
observed after one-single tDCS session in depressed patients24-26; (3) 
the top-down, neuromodulatory effects of tDCS, possibly reversing 
the imbalance between hypoactive cortical areas and hyperactive 
subcortical areas23,25, (4) the clinical effects observed in rTMS using 
either rapid, facilitatory stimulation over the left DLPFC and slow, 
inhibitory stimulation over the right DLPFC27,28.
The purpose of this review is, therefore, to summarize the find-
ings of all clinical studies using tDCS in depression hitherto, as well 
as to discuss future challenges and perspectives for using tDCS as a 
novel intervention in the therapeutic arsenal of major depression. 
Methods
We performed a literature review in PubMed/Medline, Scopus 
and Web of Science databases from English-written articles from 
1998 to December 2013. The key search terms in PubMed were: 
“transcranial direct current stimulation” OR “transcranial electric 
stimulation” AND “depressive disorder”. We did not include edito-
rials or articles reporting duplicated data. For the purposes of this 
review, meta-analyses evaluating the efficacy of tDCS in depression 
were also included.
Results
Out of 55 articles, 23 fulfilled our eligibility criteria. According to 
the study design, retrieved articles could be further classified in five 
types, as described below:
Open-label studies
Rigonatti et al.29 compared the clinical effects of active prefrontal 
tDCS vs. a six-week treatment protocol with 20 mg/day fluoxetine, 
finding that the effects of both therapies were similar. Ferrucci et al.30 
used tDCS in 14 patients with severe depression using 2mA per day, 
twice a day for 5 consecutive days, demonstrating an improvement 
of about 30% on depressive symptoms. In another study, Ferrucci et 
al.31 evaluated 32 patients, finding that tDCS improvement was bolder 
in severe depression (50%) than those in mild/moderate depression 
(10%). Brunoni et al.32 used anodal tDCS over the left DLPFC in 31 
patients (14 with bipolar and 17 with unipolar depression). Depres-
sive symptoms in both study groups improved immediately after 
the 5th session. The beneficial effect persisted after one week and one 
month. Another recent open study33 demonstrated the efficacy of 
tDCS in 23 patients with refractory depression, with a mean reduc-
tion in symptoms of 25%. Martin et al.34 performed tDCS sessions 
consecutively for 20 days, with 2mA for 20 minutes, in 11 patients 
with depression. In this open study, which placed the cathode on 
the right deltoid muscle, there was also a significant reduction in 
symptoms of about 44%. Finally, in the largest open-label sample 
to date, Brunoni et al.35, in 82 patients with unipolar and bipolar 
depression, found that five days of twice daily tDCS significantly 
improved depression symptoms. This study also showed that the 
effects of tDCS are enhanced when associated with antidepressants 
and decreased with benzodiazepines (Table 1).
Randomized, sham-controlled trials
Fregni et al.36 in the first sham-controlled, randomized clinical trial, 
found a significant decrease in the Hamilton Depression Rating Scale 
and Beck Depression Inventory after 5 days of active stimulation 
with 1mA for 20 min once daily in 10 patients, with a mean reduc-
tion in depression scores of 60-70% for active tDCS group relative 
to baseline. Similar results were demonstrated in a further study in 
antidepressant-free patients with recurrent major depressive episodes 
after 5 days of active tDCS stimulation37 with 18 patients. Boggio et 
al.38 recruited 40 patients with moderate to severe depression, evalu-
ating depression improvement after 30 days of stimulation (patients 
received 10 tDCS sessions). Only prefrontal tDCS reduced depressive 
symptoms significantly. 
After these positive results, three other studies reported negative 
findings. Loo et al.39 recruited 40 patients to receive active vs. sham 
tDCS and did not find significant differences between these groups. 
However, treatment was provided for only five treatment sessions, 
3 days per week. This study also did not exclude patients with per-
sonality disorders. Palm et al.40 recruited 22 patients with depression 
and randomized them to receive 1mA stimulation, 2mA stimulation 
or sham tDCS in a cross-over design. Active and placebo tDCS was 
applied for 2 weeks, but no differences in depression improvement 
were found. Finally, Blumberger et al.41 did not find significant dif-
ferences between active vs. sham tDCS in a tertiary sample of 24 
refractory patients. All these studies acknowledged methodological 
limitations (notably small sample sizes) that could have undermined 
the efficacy of tDCS.
In fact, two larger, recent tDCS trials observed that tDCS was an 
effective treatment for depression. Loo et al.42 randomized 64 patients 
to receive active or sham tDCS (2 mA, 15 sessions over 3 weeks), 
followed by a 3-week open-label active treatment phase. Mood and 
neuropsychological effects were assessed. There was significantly 
greater improvement in mood after active than sham treatment. 
Attention and working memory improved after a single session of ac-
tive but not sham tDCS. There was no decline in neuropsychological 
functioning after 3-6 weeks of active stimulation. Finally, our group43 
enrolled 120 antidepressant-free patients with moderate and severe 
depression who were randomized in four arms (2x2 design): sham 
tDCS and placebo pill, sham tDCS and sertraline, active tDCS and 
placebo pill and active tDCS and sertraline (the study name was 
Sertraline vs. Electric Current Therapy to Treat Depression Clini-
cal Trial – SELECT-TDCS; its design is described in44). The tDCS 
parameters were 2mA per 30 minutes/day, for 2 weeks and 2 extra 
tDCS sessions every other week until week 6 (study endpoint); the 
dose of sertraline was fixed (50 mg/day). Our main findings were 
that: (1) the combined tDCS/sertraline was significantly more ef-
fective than in the other treatment groups in reducing depressive 
symptoms; (2) tDCS and sertraline efficacy did not differ; (3) active 
tDCS as a monotherapy was also more effecitve than the placebo 
group. Of note, we also found (1) no decline in cognitive improve-
ment after tDCS or sertraline treatment; (2) 5 cases of hypomanic/
manic episodes in the combined treatment group vs. one case in 
tDCS-only, one case in sertraline-only and no cases in the placebo 
arm (although this difference was not statistically significant); (3) 
use of benzodiazepines and treatment-resistant depression were 
both predictors of lower response; (4) treatment was well-tolerated 
with mild adverse effects, which were of similar frequency in both 
arms, except for skin redness that was more prevalent in the active 
group. Biological markers were also evaluated (some of them are 
discussed below) (Table 2).
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Table 3. TDCS case reports
Author Sample (n) Anode Cathode Intensity (A/m²) Number of sessions
Palm et al., 200951 1 F3 R SO 0.28 16
Baccaro et al., 201046 1 F3 F4 0.57 5
Arul-Anandam et al., 201048 1 F3 R SO 0.28 5
Brunoni et al., 201147 1 F3 F4 0.57 5
Bueno et al., 201150 1 F3 F4 0.57 10
Galvez et al., 201149 1 F3 R arm 0.57 14
F3: left dorsolateral prefrontal cortex; F4: right dorsolateral prefrontal cortex; R arm: right arm; R SO: right supraorbital area; tDCS: transcranial direct current stimulation. Depression improvement is 
the score change in from baseline to endpoint, for each study.
Table 2. Randomized, controlled tDCS trials
Author Sample (n) Anode Cathode Intensity (A/m²) Number of sessions Outcome (score 
improvement)
Fregni  et al., 200636 10 F3 R SO 0.28 5 (every other day) 60%
Fregni et al., 200637 18 F3 R SO 0.28 5 (every other day) 58.50%
Boggio et al., 200838 40 F3 F4 0.28 10 (1x/day) 40.40%
Loo et al., 201039 40 F3 R SO 0.28 5 (every other day) 19.5%
Palm et al., 201140 22 F3 R SO 0.28/0.57 10 (1x/day) 14.6%/16.7%
Blumberger et al., 201241 24 F3 F4 0.57 15 (1x/day) 24.50%
Loo et al., 201242 64 F3 R SO 0.57 15 (1x/day) 28.40%
Brunoni et al., 201343 120 F3 F4 0.8 10 (1x/day) 29.8 %/55.6%*
F3: left dorsolateral prefrontal cortex; F4: right dorsolateral prefrontal cortex; R arm: right arm; R SO: right supraorbital area; tDCS: transcranial direct current stimulation. Depression improvement is 
the score change in from baseline to endpoint, for each study. * Represents depression improvement in the active tDCS/placebo-pill and active tDCS/sertraline arms, respectively.
Table 1. Open-label tDCS studies
Author Sample (n) Anode Cathode Intensity (A/m²) Number of sessions Depression 
improvement
Rigonatti et al., 200829 42 F3 R SO 0.57 10  (1x/day) 36.20%
Ferrucci et al., 200930 14 F3 F4 0.57 10 (2x/day) 32.1%
Ferrucci et al., 200931 32 F3 F4 0.57 10 (2x/day) 27.70%
Brunoni et al., 201132 31 F3 F4 0.57 10 (2x/day) 45.2%
Martin et al., 201134 11 F3 R arm 0.57 20 (1x/day) 42.80%
Dell’Osso et al., 201233 23 F3 F4 0.57 10 (2x/day) 31.30%
Brunoni et al., 201335 82 F3 F4 0.57 10 (2x/day) 18%
F3: left dorsolateral prefrontal cortex; F4: right dorsolateral prefrontal cortex; R arm: right arm; R SO: right supraorbital area; tDCS: transcranial direct current stimulation. Depression improvement is 
the score change in from baseline to endpoint, for each study.
Follow-up studies
Two studies evaluated the efficacy of tDCS in the maintenance phase 
of the depressive episode. We44 recruited 42 patients who were tDCS 
responders from the SELECT-TDCS trial and performed tDCS ses-
sions every other week for 3 months and then every month for 3 
additional months (tDCS sessions were interrupted earlier in case of 
relapse, characterizing failure treatment). In this follow-up study, we 
observed that treatment-resistant depression was significantly associ-
ated with an increased relapse rate (over 80% in 6 months). On the 
other hand, > 80% non-refractory patients sustained clinical response 
for at least 6 months. In this trial, the overall relapse rate in 6 months 
was around 50%, with most relapses occurring in the first 3 months. 
Another group45 also followed patients previously recruited to a ran-
domized clinical trial (n = 26) and performed weekly tDCS sessions for 
3 months, followed by tDCS sessions every other week in the remain-
ing 3 months. Similarly to our findings, a relapse rate around 50% in 
6 months was observed. However, most relapses occurred after the 3 
initial months, when tDCS sessions were spaced. Therefore, although 
the evidence is very preliminary, this trial suggests that an intensive 
continuation treatment (at least once a week tDCS session) during early 
follow-up might be recommended to sustain clinical improvement. 
Case reports
The available case reports for tDCS in depression fall into three 
scenarios: (1) report of emergent hypomanic/manic symptoms fol-
lowing tDCS46-49; (2) description of tDCS use in a specific type of 
depression (post-stroke depression)50 and (3) evaluation of clinical 
symptoms and EEG findings in a patients with treatment-resistant 
depression51 (Table 3).
Meta-analyses
The two published meta-analyses for tDCS in depression showed 
disparate results – interestingly, these meta-analyses evaluated the 
same randomized clinical trials described above (except for our facto-
rial trial that was not published yet) as they used different outcome 
measures – i.e., Kalu et al.52 employed continuous outcomes (depres-
sion improvement) and Berlim et al.53 dichotomic measures (response 
and remission) for estimating the effect size of the intervention. In an 
updated meta-analysis including data from our recent clinical trial, 
we found that active vs. sham tDCS was more effective using both 
continuous and categorical outcomes (Shiozawa et al., study under 
review), with the effect being small to moderate. 
18 Moffa AH, et al. / Rev Psiq Clín. 2014;41(1):15-20
Discussion
We reviewed 24 clinical studies (from case reports to randomized 
clinical trials) and two meta-analyses that evaluated the clinical 
efficacy of tDCS in major depression. The clinical improvement, 
considering changes in depression scores, ranged from 20-40% ac-
cording to number of tDCS applications, sample characteristics (re-
fractoriness, severity) and study design, with open-label trials show-
ing discretely better results than the active arms of sham-controlled 
trials. Such improvement is in the same range of antidepressant drug 
treatment54 and, in fact, two studies that directly compared tDCS vs. 
fluoxetine29 and sertraline43 found similar improvement rates in the 
pharmacological and non-pharmacological arms. This could suggest 
that tDCS might be a substitute for pharmacotherapy when its use is 
hindered, for instance, due to medical conditions55. The advantages 
of substituting medicines to tDCS are that the latter is virtually ab-
sent of side effects and pharmacological interactions. On the other 
hand, the necessity of daily tDCS sessions requires that the patients 
daily return to the service, undermining adhesion. In this context, 
the development of portable, “home-use” tDCS devices could help 
in this issue, as the number of visits to the clinical center would be 
dramatically reduced.
Moreover, other reviewed studies evaluated the role of tDCS as 
an augmentation strategy for pharmacotherapy, showing that the 
combined therapy of tDCS with antidepressant drugs was associated 
with superior improvement and, interestingly, that tDCS combined 
with benzodiazepine drugs presented decreased efficacy35,43. These 
findings might be explained by neurophysiological studies in healthy 
volunteers that evaluated motor evoked potential changes after 
taking a pharmacological agent (or placebo). Using this design, 
Nitsche et al.56 observed that the effects of anodal tDCS are greatly 
enhanced by the SSRI citalopram, and also that the inhibitory effects 
of cathodal tDCS changes to excitatory after citalopram. In fact, 
in ancillary SELECT-TDCS studies we found that the 5-HTTLPR 
(serotonin transporter) polymorphism impacts on tDCS response57 
and that tDCS combined to sertraline was the only treatment ef-
fective for the core symptoms of depression (depressed mood and 
anhedonia)58. Therefore, although the mechanistic foundations for 
the greater effects of the combined therapy remain elusive, one 
hypothesis is that these interventions have synergistic effects, one 
augmenting the other. 
Another critical and unclear point is the optimal treatment 
protocol during the maintenance phase. Only two follow-up 
studies were carried out hitherto44,45 with relatively poor results, 
with a relapse rate of around 50% in six months. We propose that 
the same strategies under research for rTMS could be employed 
here, namely more frequent stimulation sessions and use of an-
tidepressant drugs during the maintenance phase. Future studies 
should also explore whether patients who responded to tDCS 
and further relapse would again achieve clinical response after 
another tDCS trial. 
Finally, it should be underscored that not all clinical trials yielded 
positive results and one meta-analysis failed to show superiority 
from active tDCS to sham treatment. Some reasons for these mixed 
findings include relatively small sample sizes, disparate treatment 
modalities (including number of sessions, cathode positioning, 
duration and intensity of the sessions etc.) and different depression 
characteristics (regarding refractoriness, severity, mean age, unipolar 
vs. bipolar depression and concomitant use of pharmacotherapy) in 
the sample. In our updated meta-analysis (currently under review) 
we found tDCS effects to be statistically significant, with the effect 
size of similar magnitude than observed in clinical trials54. Nonethe-
less, further randomized clinical trials are necessary and, in fact, 
several trials are being currently performed worldwide – according 
to clinicaltrials.org (assessed online on November 27, 2013), there 
are 15 randomized clinical trials evaluating the clinical efficacy of 
tDCS in depression. Therefore, in the next years a definite answer 
regarding tDCS clinical efficacy is expected.
Conclusion
Transcranial direct current stimulation is a promising somatic 
therapy for the treatment of major depression. Low cost, easiness 
of use and absence of severe adverse effects are its main advantages. 
Further, the development of “home-use” tDCS devices might help in 
overcoming one of the main caveats in non-invasive neuromodula-
tory therapies, which is the need to perform daily visits to the clinic 
to have the stimulation sessions delivered. Although initial tDCS 
trials displayed mixed findings; recent, larger trials showed that 
tDCS was effective in depression treatment. Future ongoing stud-
ies will provide a definite answer regarding the role of tDCS in the 
therapeutic arsenal of depression. 
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